RE:RE:RE:Phase11 450 days CR% data for BTD approval in Dec 2022...You are absolutely correct CancerSlayer, but unfortuntately it seems Shareholders have no rights to express their opinion in Canada, no matter how upset they might be in the direction, even though we own part of the company ! What a strange situation. I thought being a Shareholder gave one certain rights to discuss their approval or disapproval of a companies direction !
CancerSlayer wrote:
Legit62 wrote: Wildbird, everyone keeps bringing up phase 1 results, the FDA will sure know how to look past non optimized patients when they review results, our results are very very solid at this point and should be even better next media release, share price wlll follow up, to what degree, i have no idea
Agree Legit....I have a very hard time believing the FDA would accept any invalid (or at least less valid) data from ANY trial that could ultimately compromise its final decision re: the grant of an AA, or even a BTD for that matter. Although data from the underdosed 12 may not impact our ability to get a BTD numbers wise, the final analysis & publication of trial results should NOT include this data set if scientific integrity still means anything.
My decision to invest my hard-earned money here certainly wasn't based on the possibility of quasi-scientific analysis. For the sake of sanity, general well-being & good science, we should put the under treated data set finally to rest...never to be discussed again (wishful thinking maybe ;). It functionally serves nothing more than to provide us a separate unintended cohort of patients that has no bearing whatsoever on our current ACT as recommended. All IMHO.